Estrella Immunopharma (ESLAW) Stock Analysis

What Estrella Immunopharma does

Estrella Immunopharma, Inc. is an early-stage biopharmaceutical firm based in Emeryville, California, dedicated to advancing T-cell immunotherapies for various hematological malignancies and solid tumors within the United States. Its lead investigational treatments include EB103, currently undergoing preclinical assessment for diffuse large B-cell lymphoma, and EB104, which targets both diffuse large B-cell lymphoma and acute lymphocytic leukemia. The company also collaborates with Imugene Limited to develop solid tumor therapies, integrating Imugene's candidate CF33-CD19t with Estrella's EB103.

Key metrics

ETFs linked to ESLAW

Broad-market and Healthcare sector ETFs an investor holding Estrella Immunopharma is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how ESLAW fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Estrella Immunopharma?

Estrella Immunopharma trades under the ticker ESLAW on NASDAQ.

Which exchange is ESLAW listed on?

ESLAW is listed on NASDAQ.

What sector does Estrella Immunopharma operate in?

Estrella Immunopharma is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ESLAW in a portfolio?

PortView shows ESLAW's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.